Public First Action routed $2m to support Colorado House candidate Manny Rutinel through Latino Victory Fund — and didn’t publicly announce it ahead of Rutinel’s victory

OpenAI insists it doesn’t fund or direct LTF — but one of the super PAC’s operatives describes it as a “corporate funder” with “a say”

Palantir’s fiery rhetoric helps mystify its mostly mundane tech — propping up its share price and preserving its national security contracts

This document outlines Transformer’s aims, funding, ethics policies, and editorial standards.

As a movement, it has largely refused to engage seriously with AI, ceding debate about a threat and opportunity to the right

Employees of Google DeepMind, OpenAI and Anthropic are publicly criticizing the Trump administration after Saturday’s shooting — but their bosses are staying quiet.

The EO would establish an “AI Litigation Task Force" to challenge state AI laws

Opinion: Felix M Simon argues that AI is unlikely to significantly shape election results in the near future, but warns that it could damage democracy through a steady erosion of institutional trust.

Opinion: Felix M Simon argues that AI is unlikely to significantly shape election results in the near future, but warns that it could damage democracy through a steady erosion of institutional trust.

Eliezer Yudkowsky and Nate Soares’ new book should be an AI wakeup call — shame it’s such a chore to read

Opinion: Rumman Chowdhury and Mala Kumar argue that we need better AI evaluations — and the infrastructure and investment to do them

Individual ChatGPT queries are a rounding error — we need to think about the future

We're now a team of reporters and editors dedicated to covering the power and politics of AI

A new super PAC network looks set to spend millions to influence AI regulation

It’s not AI winter just yet, though there is a distinct chill in the air. Meta is shaking up and downsizing its artificial intelligence division. A new report out of MIT finds that 95 percent of compa...

Anthropic could have to pay billions in damages — and others may follow

A host of new evidence shows that misalignment is possible — but it's unclear whether harm will follow

Learn to spot spin and subterfuge in biotech clinical trials.

Fears of ‘model collapse’ are overstated — at least for now